MannKind Corp
MNKD
£2.96
Share price
-2.46%
Change (1 day)
-34.49%
Change (1 year)
Categories
MannKind Corp (MNKD) - P/B ratio
P/B ratio as of July 2025 : -20.5
According to MannKind Corp's latest financial reports the company has a price-to-book ratio of 4.04434.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
MannKind Corp - P/B ratio (from 2004 to 2025)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2025-12-31 | N/A | -100% |
| 2024-12-31 | -23.9 | 498.66% |
| 2023-12-31 | -3.99 | -28% |
| 2022-12-31 | -5.54 | 5.56% |
| 2021-12-31 | -5.24 | 28.28% |
| 2020-12-31 | -4.09 | 185.12% |
| 2019-12-31 | -1.43 | 26.64% |
| 2018-12-31 | -1.13 | -11.83% |
| 2017-12-31 | -1.28 | -22.59% |
| 2016-12-31 | -1.66 | -6.5% |
| 2015-12-31 | -1.77 | -93.82% |
| 2014-12-31 | -28.7 | -54.1% |
| 2013-12-31 | -62.5 | 947.62% |
| 2012-12-31 | -5.97 | 470.27% |
| 2011-12-31 | -1.05 | -81.14% |
| 2010-12-31 | -5.55 | -66.79% |
| 2009-12-31 | -16.7 | -514.44% |
| 2008-12-31 | 4.03 | 82.01% |
| 2007-12-31 | 2.22 | -29.74% |
| 2006-12-31 | 3.15 | 79.01% |
| 2005-12-31 | 1.76 | -48.06% |
| 2004-12-31 | 3.39 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | P/B ratio differencediff. | Country |
|---|---|---|---|
 Halozyme Therapeutics HALO | 14.8 | -171.84% | 🇺🇸 USA |
 Novo Nordisk NVO | 15.2 | -173.80% | 🇩🇰 Denmark |
 Merck MRK | 4.36 | -121.24% | 🇺🇸 USA |
 Eli Lilly LLY | 45.8 | -322.96% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | 29.8 | -245.05% | 🇺🇸 USA |
 Pfizer PFE | 1.52 | -107.43% | 🇺🇸 USA |